Market header image

Bulletins

You are here

2017-0204 - Suspension - Abattis Bioceuticals Corp. (ATT)

February 6, 2017

Abattis Bioceuticals Corp. is in default of CSE requirements. Effective immediately, Abattis Bioceuticals will be suspended pursuant to CSE Policy 3. The suspension is considered a Regulatory Halt as defined in National Instrument 23-101 Trading Rules.  A cease trade order has been issued by the British Columbia Securities Commission and the Ontario Securities Commission.

Date: Effective immediately, February 6, 2017

Symbol: ATT

If you have any questions or require further information please contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com

Advertisement

Publicité

Latest CSE News

Upcoming Events

09-22_Extraordinary_Future_2019_Website

Extraordinary Future 2019

Sunday, September 22, 2019 (All day) to Monday, September 23, 2019 (All day)
09-26_4th_CEO_Summit_2019-Website

4th CEO Summit 2019

Thursday, September 26, 2019 -
9:00am to 1:30pm

Advertisement

Publicité